



For further information please contact:

ANTISENSE PHARMA GmbH
Ms. Ursula Dalferth / Public Relations
Josef-Engert-Str. 9 / D-93053 Regensburg
Phone ++49-941-92013-0 / Fax -29
e-mail: pr@antisense-pharma.com

Press Release

ASCO ACCEPTS ANTISENSE PHARMA'S CLINICAL PHASE I/II RESULTS OF AP 12009 IN HIGH-GRADE GLIOMA FOR ORAL POSTER DISCUSSION AT THE 2004 ANNUAL MEETING

REGENSBURG, GERMANY - May 13th, 2004. Antisense Pharma GmbH announced today that data from the Company's phase I/II AP 12009 trials in high-grade glioma have been accepted as the subject of a poster discussion session at the 2004 Annual Meeting of the American Society of Clinical Oncology (ASCO). The meeting will take place in New Orleans, Louisiana, June 5-8. Poster discussion sessions at ASCO annual meetings highlight extraordinary clinical research results out of thousands of submitted abstracts.

The lead investigator, Prof. Ulrich Bogdahn, MD, University of Regensburg, Germany, will present the poster 'Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-beta2 specific antisense oligonucleotide AP 12009' (Poster No: 5, Abstract No: 1514) in the session 'Central Nervous System Tumors' on Saturday, June 05, 2004, 4:00 p.m. - 5:00 p.m. in R06 (2nd Floor). The poster will be displayed from 1:00 p.m. to 5:00 p.m. in R08 (2nd Floor). AP 12009 was administered intratumorally in three phase I/II studies and revealed excellent safety and tolerability. 7 out of 24 patients showed a stabilization or response including two patients with a long-lasting complete remission. AP 12009 is now applied in an international phase II/III study in comparison to standard chemotherapy.

Antisense Pharma has also been notified that preclinical data of AP 12009 in pancreatic cancer are scheduled to be presented in a poster presentation. The poster 'TGF-beta2 suppression by the antisense oligonucleotide AP 12009 as treatment for pancreatic cancer: Preclinical efficacy data' (Poster No: V10, Abstract No: 4106) will be presented on the same day, Saturday, June 05, 2004, 1:00 p.m. - 5:00 p.m., in Hall A (right half). Based on preclinical efficacy of AP 12009 in tumor proliferation, migration and inhibition of escape from immunosurveillance in pancreatic cancer a multi-site phase I trial with AP 12009 in pancreatic cancer is currently being started.

The third submitted abstract was also accepted for publication at ASCO and describes the preclinical studies performed with AP 11014, a TGF-beta1 antisense inhibitor, for the treatment of non-small cell lung, colorectal and prostate cancer.

This press release contains forward-looking statements with respect to the future business of Antisense Pharma GmbH. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that could occur in the future. There is a number of factors that could cause actual results and developments to differ materially. Antisense Pharma GmbH disclaims any intent or obligation to update any of these forward-looking statements.